Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology

Fig. 1

JAK-STAT pathway with JAK inhibitor targets. The activation of the JAK-STAT pathway after IFN type 1 has engaged with the associated receptor, IFNR. This induces the transcription of proteins. Tofacitinib inhibits JAK1/2/3. Ruxolitinib and Baricitinib inhibit JAK 1/2, inhibtion prevents STAT phosphorylation, dimeraziation and transolcation into the nucleuse. This in turn stops the transcription of pro-inflammatory proteins

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096